Pharma Stability: Insights, Guidelines, and Expertise
Global regulatory bodies such as the CDSCO, USFDA, and EMA scrutinize how OOS results are interpreted and acted upon. Improper classification of a lab error as a valid OOS — or vice versa — can result in:
Click to read the full article.
Regulatory agencies like USFDA, EMA, and CDSCO expect that all employees involved in testing and documenting stability data understand:
Click to read the full article.
A generic drug manufacturer submitted a 12-month stability study on coated tablets stored under 25°C/60% RH conditions. During testing, the assay value for batch #B091 fell below the acceptance limit of 95.0% — triggering an OOS result (reported value: 93.1%). The analyst followed standard procedures and documented the OOS event.
Click to read the full article.
Stability studies require tightly controlled environmental conditions such as 25°C/60% RH or 40°C/75% RH. A deviation — even for a few hours — can compromise the integrity of test results. Excursions may arise from:
Click to read the full article.
Extending the stability study is not always the default response. The decision depends on:
Click to read the full article.
Structured SOPs provide:
Click to read the full article.
Though the underlying principles are similar, the specific terminologies and scopes slightly differ:
Click to read the full article.
Shelf life, or the expiry date, is determined based on long-term and accelerated stability data generated per ICH Q1A(R2) guidelines. Typically, shelf life is assigned using:
Click to read the full article.
Internal audits act as a dry run before regulatory inspections. They help identify:
Click to read the full article.
The FDA adopts the ICH Q1A(R2) guideline for stability testing of new drug substances and products. However, it may require additional details as per regional expectations. Key references include:
Click to read the full article.